Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
KLCI extends gains on bargain hunting, stronger ringgit

2018-07-10 theedgemarkets
KUALA LUMPUR (July 10): Bargain hunting helped the FBM KLCI close in positive territory for the second day running today, after hitting an 18-month low.
TGLVY 4863 7251 3301 SMEBF 7113 4197 TPGVF MYTEF 7277

0
Regional markets jittery but KLCI bucks trend

2018-07-05 thestar.com.my
KUALA LUMPUR: Share prices on Bursa Malaysia closed higher on Thursday on last minute support for index-linked heavyweight counters.
4863 PBLOF SMEBF 4197 MYTEF 1295 BSMAF 1818

0
Sime Darby’s Weifang disposal a positive

2018-07-04 theedgemarkets
Sime Darby Bhd (July 3, RM2.35) Maintain neutral with an unchanged target price (TP) of RM2.40: Sime Darby Bhd announced that its indirect wholly-owned subsidiary, Sime Darby Overseas (HK) Ltd, had entered into a share purchase agreement with Shandong Water Environmental Protection Group Co Ltd (Shuifa) to divest its entire 100% equity interest in Weifang Sime Darby Water Management Co Ltd (WSDW) for a total cash consideration of US$68 million (RM275 million).
SMEBF 4197

0
Analyst reports

2018-07-03 thestar.com.my
Maybank IB said the fall in earnings stemmed from both revenue decline (discontinuation for Keurig’s products) and higher costs (for a new beauty care products in the pipeline).
SMEBF 4197

0
Most fall ahead of U.S. tariff deadline; Indonesia at over 1-yr low

2018-07-03 theedgemarkets
(July 3): Most Southeast Asian stock markets fell on Tuesday, as a rout in Chinese shares ahead of a U.S. deadline for further tariffs on exports from the world's second-largest economy soured risk sentiment across the region.
5347 DBSDY D05 SMEBF DBSDF TNABY 4197 TNABF O39

0
The Week Ahead: Awaiting Cabinet line-up and new Umno president

2018-07-03 theedgemarkets
THE ringgit, which last week breached the psychological RM4 mark against the US dollar for the first time in five months, is in the spotlight again. At the time of writing last Friday (June 22), the ringgit fetched 4.0022 against the greenback. The ringgit’s fair value should be 3.80, Prime Minister Tun Dr Mahathir Mohamad told Bloomberg in a June 22 interview. “We would like to strengthen our ringgit, but it should be done naturally,” he said.
SARKF MLYNF 8664 6521 7237 1171 5158 8583 0012 4898 3883 5126 7229 SMEBF 5703 MYTEF MLYBY 4197 5202 7164 5222 1155 4588 4863 3158 4723

0
Most South-east Asian stocks fall, Indonesia at over one-year low

2018-07-03 malaymail
SINGAPORE, July 3 — Most South-east Asian stock markets fell today as a rout in Chinese shares ahead of a US deadline for further tariffs on exports from the world's second-largest economy soured risk sentiment across the region.
5347 DBSDY D05 SMEBF DBSDF TNABY 4197 TNABF O39

0
KLCI poised to extend losses, down 0.43% tracking region

2018-07-03 theedgemarkets
KUALA LUMPUR (July 3): The FBM KLCI looked set to extend its losses today in line with the turbulent regional markets, as it fell 0.43% at the midday break.
HLFBF 5270 UPBMF 8621 7036 1082 4197 5681 BATS 4162 1163 2089 5199 KLKBY 2445 5347 3867 SMEBF TNABY TNABF HIPEF 3719

0
Sime Darby shares down on China business divestment news

2018-07-03 malaymail
KUALA LUMPUR, July 3 — Sime Darby Bhd was actively traded in the morning session today after entering into an agreement to divest its entire equity interest in China-based Weifang Sime Darby Water Management Co Ltd (WSDW) for about RM275 million in cash.
SMEBF 4197

0
Sime Darby plans to sell Weifang Water for RM275m

2018-07-03 theedgemarkets
KUALA LUMPUR: Sime Darby Bhd has proposed a divestment of its China-based water management business, Weifang Sime Darby Water Management Co Ltd (Weifang Water) for US$68 million or 450 million yuan (RM274.72 million).
SMEBF 4197

5
Sime sells China-based unit for RM275mil

2018-07-02 thestar.com.my
KUALA LUMPUR: Sime Darby Bhd is selling its China-based water management business, Weifang Sime Darby Water Management Co Ltd, to Shandong Water Environment Protection Group Co Ltd for US$68mil (RM275mil).
SMEBF 4197

5
Sime Darby to sell China-based water management biz for RM275m

2018-07-02 theedgemarkets
KUALA LUMPUR (July 2): Sime Darby Bhd has proposed a divestment of its China-based water management business, Weifang Sime Darby Water Management Co Ltd (Weifang Water), for US$68 million or RMB450 million (around RM275 million).
SMEBF 4197

5
Sime Darby to sell China-based water company for RM275m

2018-07-02 malaymail
KUALA LUMPUR, July 2 — Sime Darby Bhd has proposed to divest its China-based water management business, Weifang Sime Darby Water Management Co Ltd (Weifang Water), for US$68 million or approximately RM275 million.
SMEBF 4197

7
Zeti replaces Wahid as PNB chairman

2018-06-30 thestar.com.my
Zeti, like Wahid, brings immediate credibility that is important in driving the business direction of the fund.
1155 4863 MLYBY SMEBF MLYNF 4197 MYTEF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

48m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...